Exocrine Pancreatic Insufficiency Market Report 2026

Exocrine Pancreatic Insufficiency Market Overview

• Exocrine Pancreatic Insufficiency market size has reached to $2.75 billion in 2025 • Expected to grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Increasing Prevalence Of Chronic Diseases Boosts Growth Prospects For The Exocrine Pancreatic Insufficiency (EPI) Market • Market Trend: Exocrine Pancreatic Insufficiency Market Grows With Patient Advocacy And Nutritional Support Initiatives • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Exocrine Pancreatic Insufficiency Market?

Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the pancreas's insufficient production or release of digestive enzymes into the small intestine. These enzymes are essential for the digestion and absorption of nutrients from food. Exocrine pancreatic insufficiency can lead to malnutrition and digestive symptoms, including diarrhea, abdominal pain, bloating, and weight loss. The main types of exocrine pancreatic insufficiency treatments are nutritional management, pancreatic enzyme replacement therapy (PERT), and others. Nutritional management refers to the practice of planning and implementing dietary strategies to optimize an individual's nutritional status and support their overall health and well-being, and it also plays a crucial role in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed with imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others to identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, weight loss, and others. The drugs are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other channels that are used in the treatment of exocrine pancreatic insufficiency by end users, including hospitals, specialty clinics, and homecare.

What Is The Exocrine Pancreatic Insufficiency Market Growth Forecast?

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to advancements in enzyme formulation technologies, rising geriatric population, increasing demand for homecare treatment, growth of online pharmacies, improved reimbursement for digestive disorder treatments. Major trends in the forecast period include increased adoption of pancreatic enzyme replacement therapy, rising focus on early and accurate diagnosis, growth in home-based nutritional management, expansion of online pharmacy distribution, improved patient awareness and education programs.

Global Exocrine Pancreatic Insufficiency Market Segmentation

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments 2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types 3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End Users: Hospitals, Specialty Clinics, Homecare Subsegments: 1) By Nutritional Management: Dietary Modifications, Nutritional Supplements 2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations 3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies

What Is The Driver Of The Exocrine Pancreatic Insufficiency Market?

The rise in chronic diseases is expected to propel the growth of the exocrine pancreatic insufficiency market going forward. Chronic diseases are long-term medical conditions that persist over an extended period, typically three months or more. The prolonged presence of the underlying disease can also increase the likelihood of developing secondary complications like exocrine pancreatic insufficiency, which fuels the better management of chronic conditions through medical interventions and therapies and can lead to longer life spans for individuals with these conditions. For instance, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths occur annually, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases worldwide. Therefore, the rise in chronic diseases will drive the growth of the exocrine pancreatic insufficiency industry.

Key Players In The Global Exocrine Pancreatic Insufficiency Market

Major companies operating in the exocrine pancreatic insufficiency market are Nestlé Health Science S.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Enzymedica Inc., Alcresta Therapeutics Inc., Chiesi Farmaceutici S.p.A., Amryt Pharma Plc, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Medtronic plc, First Wave BioPharma Inc., Vivus Inc., Abbott Laboratories, Danone S.A., Fresenius SE & Co. KGaA, Baxter International Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc, Koninklijke Philips N.V., Fujifilm Holdings Corporation

Global Exocrine Pancreatic Insufficiency Market Trends and Insights

Major companies operating in the exocrine pancreatic insufficiency market are focusing on creating patient advocacy groups, such as comprehensive nutritional guidance, to provide comprehensive nutritional guidance and support. These initiatives aim to improve awareness, education, and management of the condition among affected individuals. Comprehensive nutritional guidance is a holistic approach that tailors dietary recommendations based on individual needs, health conditions, and lifestyle. It emphasizes education, meal planning, and sustainable practices to promote overall well-being. For instance, in June 2024, Nestlé Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. Nestlé Health Science's GLP-1 nutrition support platform offers tailored nutritional resources and expert guidance for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and overall wellness. Its purpose is to empower users in their weight management journey by addressing unique dietary needs and fostering community support.

What Are Latest Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency Market?

In December 2023, Codexis, a US-based pharmaceutical company, acquired a Nestlé Health Science company for an undisclosed amount. Codexis aims to monetize its asset CDX-7108, focus on core projects, and leverage Nestlé's expertise to accelerate development while retaining economic interest. Nestlé Health Science, a Switzerland-based science-based nutrition company, provides specialized nutritional products to support individuals with exocrine pancreatic insufficiency by improving digestion and nutrient absorption.

Regional Outlook

North America was the largest region in the exocrine pancreatic insufficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Exocrine Pancreatic Insufficiency Market?

The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Exocrine Pancreatic Insufficiency Market Report 2026?

The exocrine pancreatic insufficiency market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.